Literature DB >> 18475652

Myeloperoxidase and eosinophil cationic protein in serum and sputum during antibiotic treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection.

B Niggemann1, T Stiller, K Magdorf, U Wahn.   

Abstract

I order to study the time-course of myeloperoxidase (MPO) and eosinophil cationic protein (ECP) as parameters for monitoring inflammation in cystic fibrosis (CF), we investigated ten patients during both a 14-day intravenous antibiotic treatment and a corresponding self control. Modified Shwachman-Kulczycki score improved significantly (p < 0.008), C-reactive protein (CRP) levels decreased significantly (p < 0.05) during antibiotic treatment, while in the control phase there were no significant differences. Lung function parameters did not change significantly during antibiotic treatment or control phase. Serum MPO concentration (p < 0.006) and peripheral blood neutrophil granulocyte counts (p < 0.04) decreased significantly during antibiotic treatment, but not during the control phase. Sentm ECP concentration showed a tendency to decrease during antibiotic treatment, but this failed to reach significance. In general, sputum concentrations of MPO and ECP Were 500- to 1000-fold higher than in serum. However, neither MPO nor ECP in sputum showed a significan variation over time during antibiotic treatment or control phase. From our data we conclude that: (1) measurements of MPO, neutrophils and CRP in peripheral blood do correlate with clinical parameters such as the modified Shwachman-Kulczycki score; (2) neutrophils and MPO seem to reflect inflammatory changes induced by antibiotic treatment; (3) eosinophils may play a role in CF by an enhanced 'releasability' and (4) Sputum measurements of mediators of inflammation cannot be recommended.

Entities:  

Year:  1995        PMID: 18475652      PMCID: PMC2365643          DOI: 10.1155/S0962935195000457

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  18 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  The systematic evaluation of the chest radiograph in cystic fibrosis.

Authors:  A R Chrispin; A P Norman
Journal:  Pediatr Radiol       Date:  1974

3.  The onset and recovery from airway hyperresponsiveness: relationship with inflammatory cell infiltrates and release of cytotoxic granule proteins.

Authors:  R H Gundel; C D Wegner; L G Letts
Journal:  Clin Exp Allergy       Date:  1992-02       Impact factor: 5.018

4.  T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis.

Authors:  M Azzawi; P W Johnston; S Majumdar; A B Kay; P K Jeffery
Journal:  Am Rev Respir Dis       Date:  1992-06

5.  Neutrophil and eosinophil granulocytes in bacterial infection: sequential studies of cellular and serum levels of granule proteins.

Authors:  P Venge; A Strömberg; J H Braconier; L E Roxin; I Olsson
Journal:  Br J Haematol       Date:  1978-04       Impact factor: 6.998

6.  Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone.

Authors:  W E Regelmann; G R Elliott; W J Warwick; C C Clawson
Journal:  Am Rev Respir Dis       Date:  1990-04

Review 7.  Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.

Authors:  N Høiby; C Koch
Journal:  Thorax       Date:  1990-11       Impact factor: 9.139

8.  The eosinophil component of the alveolitis in idiopathic pulmonary fibrosis. Signs of eosinophil activation in the lung are related to impaired lung function.

Authors:  R Hällgren; L Bjermer; R Lundgren; P Venge
Journal:  Am Rev Respir Dis       Date:  1989-02

9.  Inflammatory markers in cystic fibrosis.

Authors:  R J Rayner; M S Wiseman; S M Cordon; D Norman; E J Hiller; D J Shale
Journal:  Respir Med       Date:  1991-03       Impact factor: 3.415

10.  Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo.

Authors:  C G Peterson; I Enander; J Nystrand; A S Anderson; L Nilsson; P Venge
Journal:  Clin Exp Allergy       Date:  1991-09       Impact factor: 5.018

View more
  1 in total

1.  Recombinant Myeloperoxidase as a New Class of Antimicrobial Agents.

Authors:  Zehong Cao; Guangjie Cheng
Journal:  Microbiol Spectr       Date:  2022-01-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.